[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:yolk-sac-tumor":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":41,"states":45},"Yolk Sac Tumor",5,4,[8,16,22,28,34],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[12],"Phase 1","RECRUITING","2026-08-26T02:16:39.977107Z","2026-05-05T02:43:29.711287Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[12],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.698343Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[12],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:27.425045Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT05564026","Molecular Epidemiology of Pediatric Germ Cell Tumors",[],"2026-08-26T02:16:46.147215Z","2026-05-13T02:55:06.362642Z",{"nct_id":35,"title":36,"phases":37,"status":38,"updated_at":39,"content_modified":40},"NCT07224568","Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:26.899812Z",[42],{"biomarker":43,"count":6,"slug":44},"Glypican-3","glypican-3",[]]